State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and ...

Alopecia areata affects ~2% globally and is associated with atopic/autoimmune overlap, psychological comorbidity, and a ...

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages. A key driver of that burden is recognition—or ...

A 546-patient, multicountry phase 3 trial randomized participants on insulin glargine (± metformin/SGLT2 inhibitors) to ...

Influenza vaccine coverage increased 7.4% from 2017-2018 to 2019-2020, then fell 12.9% from 2019-2020 to 2022-2023 in this ...

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and ...

Anne Komé, PharmD, CPP, BCACP, CDCES, a clinical pharmacist practitioner in the Endocrinology Clinic at the UNC Chapel Hill ...

Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and ...

Inhaled insulin (Afrezza; MannKind Corporation) continues to build a case for broader adoption in pediatric diabetes care.

Patients need more than information. They need personal guidance relevant to what they’re facing in the moment. Nurse-led ...

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician ...